Solid Biosciences Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Solid Biosciences Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $291.00K, a 47.72% increase year-over-year.
- Solid Biosciences Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $197.00K, a 35.86% increase year-over-year.
- Solid Biosciences Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-06-30 was $145.00K, a 85.90% increase year-over-year.
- Solid Biosciences Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-06-30 was $78.00K, a 6.85% increase year-over-year.
- Solid Biosciences Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $425.00K, a 26.11% increase from fiscal 2024.
- Solid Biosciences Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $337.00K, a 127.70% increase from fiscal 2023.
- Solid Biosciences Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $148.00K, a 18.23% decline from fiscal 2022.
- Solid Biosciences Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $181.00K, a 174.24% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $291.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $425.00K 10-K · filed 2026-03-19 | |
| 2025-06-30 | $197.00K 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $337.00K 10-K · filed 2026-03-19 | |
| 2024-06-30 | $145.00K 10-Q · filed 2025-11-03 | |
| 2023-12-31 | $148.00K 10-K · filed 2025-03-06 | |
| 2023-06-30 | $78.00K 10-Q · filed 2024-11-06 | |
| 2022-12-31 | $108.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $181.00K 10-K · filed 2024-03-13 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | |
| 2022-06-30 | $73.00K 10-Q · filed 2022-08-11 | |
| 2021-12-31 | $66.00K 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |